Clinical trial
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With…
NCT00387933 · Duke University, Other · Completed
Key facts
| NCT number | NCT00387933 |
|---|---|
| Title | Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma |
| Official title | Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | hydroxyurea, imatinib mesylate, vatalanib |
| Enrollment | 37 |
| Start date | Jul 1, 2005 |
| Primary completion | Jan 1, 2009 |
| First posted | Oct 13, 2006 |
| Last update posted | Oct 14, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: